Progress in the Management of Malignant Pleural Mesothelioma in 2017 - ScienceDirect
Mesothelioma Cell Growth Affected by ADI-PEG 20 Plus Chemotherapy
Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism - ScienceDirect
Frontiers | Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Benign Mesothelioma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma
ADI-PEG 20 treatment during PBMC stimulation and not under resting... | Download Scientific Diagram
Onco | Free Full-Text | Pre-Clinical Research Advancements Relating to Improving the Diagnosis and Treatment of Malignant Pleural Mesothelioma: A Review
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Arginine deprivation for ASS1-deficient mesothelioma
Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM | Cell Death & Disease
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Ple
Combination of Arginine Deprivation with TRAIL Treatment as a Targeted-Therapy for Mesothelioma | Anticancer Research
Novel therapies for malignant pleural mesothelioma - The Lancet Oncology
Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase–Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase - ScienceDirect
Mesothelioma: Current Best Practices and Promising Therapies - ppt download
Combination of Arginine Deprivation with TRAIL Treatment as a Targeted-Therapy for Mesothelioma | Anticancer Research
A trial of a new drug called ADI-PEG 20 with chemotherapy for people with mesothelioma (ATOMIC-Meso) | Cancer Research UK
Frontiers | Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Polaris Group receives orphan drug designation for ADI-PEG 20 from the FDA
ADI-PEG 20 reduces B16-F10 tumor growth as a single agent and in... | Download Scientific Diagram
Accelerating innovations in systemic therapy for pleural mesothelioma | Nature Cancer
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies | British Journal of Cancer
Frontiers | A Glimpse in the Future of Malignant Mesothelioma Treatment
